Independent U.S. Market Research

Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research

Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.

Merlintrader’s Daily Briefing

Wednesday, August 12, 2026, morning edition, written before the U.S. opening bell. Tuesday was the second consecutive lower close on Wall Street, with the S&P 500 down 0.32% as optimism over a Washington–Tehran arrangement on the Strait of Hormuz faded and crude held its gains. Overnight the tone improved: South Korea led Asia sharply higher on technology earnings, U.S. futures ticked up, and CoreWeave’s results after the bell added to the artificial-intelligence infrastructure story. Everything now waits on one number. July consumer prices arrive at 8:30 a.m. Eastern, with the consensus looking for a 0.1% monthly increase after June’s decline, into a bond market that is heavily positioned for a hot print and a Fed voter who has just argued for more than one further rate increase.

Tuesday’s close
  • $SPX — The S&P 500 closed at 7,728.20, down 0.32%, a second straight decline that takes the index roughly 30 points below Friday’s record. The move was orderly rather than defensive, but the direction was consistent across the session.Equities
  • $COMP — The Nasdaq Composite lost 0.6% to 26,445.45, the weaker of the three headline gauges, with megacap technology giving back part of last week’s advance. Alphabet was among the notable decliners.Equities
  • $DJI — The Dow Jones Industrial Average fell 184.13 points, or 0.34%, to 53,791.85. All three indexes finished in the red for the second session running.Equities
  • Hormuz — The proximate cause was diplomatic rather than economic. Doubts hardened over whether Washington and Tehran are close to an arrangement to reopen the Strait of Hormuz, and equities faded through the final hour as those hopes dimmed.Geopolitics
  • Energy — Energy was again the part of the market with a bid, the mirror image of the drag that higher crude imposes on transport, consumer and industrial margins. That split has now persisted for several sessions.Sectors
Overnight and the futures
  • $KOSPI — South Korea led the region, with the Kospi up 2.44% in intraday trade after an earlier 1.5% advance, carried by technology results and by reports of fresh foreign investment in the memory complex.Asia
  • $NKY — Japan reopened after a public holiday with a far more subdued session. The Nikkei 225 added 0.076% and the broader Topix 0.34%, a muted catch-up rather than a follow-through.Asia
  • Asia breadth — MSCI’s Asia Pacific gauge rose 0.4%, but Hang Seng futures slipped 0.4%, so the regional advance was concentrated rather than broad. Hong Kong is not participating.Asia
  • Memory — SK Hynix and Samsung Electronics extended their gains on a report that Temasek is preparing to invest, keeping the memory and artificial-intelligence hardware trade in the foreground across Asian hours.Semis
  • $TATA — Tata Group stocks fell sharply in India after a report that the chairman of Tata Sons has resigned, an idiosyncratic shock in a market already watching elevated crude.Asia
  • Futures — U.S. equity index futures were around 0.1% higher into the European morning, inching up ahead of the inflation report rather than taking a position on it.Equities
Oil, rates, metals and the dollar
  • Brent — Brent slipped toward $87 a barrel during Tuesday before recovering to about $88.70 after Pakistan signalled that the United States and Iran could be closer to an arrangement to ease tensions around the strait.Energy
  • WTI — The U.S. benchmark held in the low $82 area after Monday’s settlement of $82.13, itself a jump of roughly 5%. Two sessions of gains have taken crude back to the upper end of its recent range.Energy
  • Conditions — Tehran has asked for compensation as a condition for reopening the waterway and has set out six requirements, including an end to what it describes as aggression against Iran and its allies. That is a negotiation measured in weeks, not hours.Geopolitics
  • $US10Y — The ten-year Treasury yield rose to 4.73%, up about two basis points. Barclays argues that selective buyers are keeping yields pinned near multiyear highs, and trend-following funds are carrying a large short into the inflation print.Rates
  • Gold — Gold ended Tuesday at $4,367.23 an ounce, down 0.55%, then firmed overnight as traders positioned for the inflation number and geopolitical risk stayed live.Metals
  • Yen — The effect of the recent intervention is wearing off, and options desks report demand for flexibility rather than direction into the release. The yen is the currency most exposed to a surprise in either direction.FX
Wednesday’s inflation print
  • $CPI — July consumer prices are released at 8:30 a.m. Eastern. The FactSet consensus is a 0.1% monthly increase after June’s unexpected 0.4% decline, with the annual rate easing to 3.4% from 3.5%.Macro
  • Core — Core prices are forecast to rise 0.1% on the month after being flat in June. Economists surveyed by Dow Jones look for a core annual rate of 2.5%, cooler than June’s 2.6%. Stable petroleum product prices are the main reason the forecasts are soft.Macro
  • $FED — Cleveland Fed President Beth Hammack, who voted to raise rates last month, said more than one increase may be needed to bring inflation back down. That is the hawkish end of the committee arguing its case in public before the data.Fed
  • Positioning — Trend-following funds are running a large short in bonds into the release, which raises the cost of a soft number for anyone on that side of the trade and makes the reaction function asymmetric.Rates
After the close: artificial-intelligence infrastructure
  • $CRWV — CoreWeave beat on both lines, with an adjusted loss of $1.03 a share against the $1.20 expected and revenue of $2.58 billion versus $2.56 billion, up 112% year on year. Revenue backlog now exceeds $104 billion and shares rose about 13% after hours to $102.21.Earnings
  • $CRWV — The operating detail was the capacity build: 51 active data centers and 1.5 gigawatts of active power as of June 30, with contracted power at roughly 3.7 gigawatts. New business with Anthropic and Meta was named in the quarter.AI
  • $SMCI — Super Micro Computer reported fiscal fourth-quarter results after the close and the forecast sent shares higher. The July preliminary update had already flagged revenue near the low end of the $11.0 billion to $12.5 billion range, gross margin of 15% to 17% against guidance of 8.2% to 8.4%, and more than $60 billion of new orders in the quarter.Earnings
  • $NVDA — Credit markets calmed after Nvidia’s chief executive clarified the structure of the $500 billion financing plan, easing the perceived risk that had been building around the vendor-financing question.Credit
Corporate and deal news
  • $BX — Blackstone struck a $1.8 billion deal for Air Canada’s loyalty unit, another loyalty-programme carve-out in a format that private capital has repeatedly found attractive.M&A
  • Kone — U.S. authorities opened an in-depth antitrust review of the Kone–TK Elevator transaction, extending a timetable that had been expected to run more smoothly.M&A
  • $UBER — Uber exited its stake in Serve Robotics as the delivery alliance between the two companies unwound, a reminder that autonomy partnerships are not permanent.Corporate
  • $CME — CME Group is launching futures on artificial-intelligence computing power, turning compute capacity into a tradable asset class and giving data-centre operators a hedging instrument they have not previously had.Catalyst
Biotech and the Merlintrader watchlist
  • $PDSB — PDS Biotechnology fell 64.9% to $0.26 after announcing a board-led strategic refocus. The company will prioritise the immunocytokine PDS0301 in metastatic colorectal cancer and discontinue internal funding of the Phase 3 VERSATILE-003 trial of PDS0101, seeking partners or external funding for that asset instead.Biotech
  • $PDSB — The pivot rests on Phase 2 data in microsatellite-stable, mismatch repair-proficient colorectal cancer showing a 71% objective response rate at six months and 80% survival at 24 months in patients with liver metastases, with safety across more than 380 treated patients.Biotech
  • $STIM — Neuronetics rose 47% to $3.19 after second-quarter revenue of $41.6 million, up 9.1% and above the $40.2 million consensus, with the first positive adjusted EBITDA of $0.3 million against a consensus of negative $3.7 million. The net loss narrowed to $3.4 million from $10.1 million.Biotech
  • $GERN — Geron closed at $1.63, up 10.1%, without a company release dated Tuesday. The last corporate update was the August 5 second quarter, which reported RYTELO net product revenue of $57.5 million, up 11% sequentially, cash of $326.9 million and reiterated full-year revenue guidance of $220 million to $240 million.Watchlist
  • Watchlist — Among the covered names, AST SpaceMobile ended at $71.63, up 4.2%, Archer Aviation at $6.79, up 8.5%, and Rocket Lab at $80.01, essentially unchanged. Oklo added 5.7% to $47.01, BigBear.ai 3.1% to $3.33 and Palladyne AI 2.3% to $6.33, while Palantir slipped 0.2% to $174.94. Prices are Finviz Elite closes.Movers
The rest of the week
  • Thursday — July producer prices and weekly jobless claims follow on Thursday, and weekly EIA crude inventories land on Wednesday morning into an oil market already trading on supply headlines.Macro
  • Friday — Retail sales close the week. Three inflation-sensitive releases in three sessions leave little room for any single print to be dismissed as noise, and Cisco Systems reports on Wednesday evening.Macro
Read the full Daily BriefingRead the Weekly Market Pulse

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: August 8 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when the regulatory process is still materially open. October and later events are excluded from this widget.

35Active
18FDA / Reg
17Data / Filing
Aug 8Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$NRXPKETAFREEOngoingFDA reviewFirst-cycle review complete; vial certification remains

NRx Pharmaceuticals. The July 29 GDUFA goal date has passed, but the file is no longer accurately described as having “no outcome.” On August 7, NRx reported that FDA completed the first-cycle review of the ANDA for preservative-free intravenous ketamine with no major deficiencies related to the drug product, ingredients, proposed labeling, CMC or other drug-related matters. One major deficiency remains tied to the container-closure system: manufacturer certification concerning the luer-lock vial tip. Following an August 6 clarification meeting, FDA requested signed documentation and, according to the company, intends to review it in the shortest applicable cycle. No new exact action date has been disclosed.

$REGNgaretosmabAugBLAPriority Review in adult FOP

Regeneron. The BLA for garetosmab in adults with fibrodysplasia ossificans progressiva remains under Priority Review. Regeneron continues to guide to an FDA decision in August 2026 without disclosing an exact day.

$LNTHMK-6240Aug 13NDATau PET imaging in Alzheimer’s disease

Lantheus. PDUFA target date for the MK-6240 NDA. The F-18 PET imaging agent is intended to visualize tau pathology in Alzheimer’s disease. This is a diagnostic and imaging catalyst, not a therapeutic-efficacy binary.

$BMYiberdomide comboAug 17NDARRMM · iberdomide + daratumumab/dexamethasone

Bristol Myers Squibb. Priority Review PDUFA for iberdomide combined with daratumumab and dexamethasone in relapsed or refractory multiple myeloma. The application also has Breakthrough Therapy Designation for this indication.

$CAPRderamiocelAug 22Extreme riskPDUFA after 9–3 negative AdCom efficacy vote

Capricor. The resubmitted BLA for deramiocel in Duchenne muscular dystrophy-associated cardiomyopathy remains formally under review with an August 22 action date. On July 29, the advisory committee voted 9–3 that the available evidence did not provide the required substantial evidence of effectiveness. FDA is not bound by the vote, but the negative panel result, disputes over endpoint interpretation and the prior CRL make this an exceptionally high-risk regulatory event.

$RAREDTX401Aug 23BLAGene therapy for GSDIa

Ultragenyx. Priority Review PDUFA for the DTX401 (pariglasgene brecaparvovec) BLA in glycogen storage disease type Ia. The company reaffirmed the August 23 date in its August 4 update.

$JAZZZiihera comboAug 25sBLAFirst-line HER2-positive GEA

Jazz Pharmaceuticals. Priority Review PDUFA for the Ziihera (zanidatamab-hrii) sBLA in combination with chemotherapy, with or without tislelizumab, for first-line locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.

$GILDBIC/LENAug 27NDAOnce-daily oral HIV regimen

Gilead. Priority Review PDUFA for the bictegravir 75 mg/lenacapavir 50 mg NDA, a once-daily single-tablet regimen for virologically suppressed adults with HIV. This is a strategic lifecycle catalyst for the HIV franchise.

$PTGXrusfertideAugNDAPriority Review in polycythemia vera

Protagonist / Takeda. The rusfertide NDA in polycythemia vera is under Priority Review with a publicly disclosed August 2026 PDUFA goal month. Because no independently verifiable exact day has been published, this board correctly shows the month only.

$TLXPixclaraSep 11NDAPET imaging in glioma

Telix Pharmaceuticals. PDUFA target date for the resubmitted Pixclara (TLX101-Px) NDA. The PET imaging agent is intended to help characterize suspected recurrent or progressive glioma versus treatment-related changes.

$RAREUX111Sep 19BLAGene therapy for Sanfilippo syndrome type A

Ultragenyx. PDUFA for the resubmitted UX111 (rebisufligene etisparvovec) BLA in Sanfilippo syndrome type A. The company reaffirmed September 19 in its August 4 update; the application seeks accelerated approval.

$MRKWINREVAIRSep 21sBLAPAH · HYPERION-based label update

Merck. PDUFA for an sBLA seeking a U.S. label update for WINREVAIR (sotatercept-csrk) based on the Phase 3 HYPERION study in pulmonary arterial hypertension. Merck reaffirmed the September 21 date with its second-quarter results.

$IONSzilganersenSep 22NDAAlexander disease

Ionis. Priority Review PDUFA for the zilganersen NDA in Alexander disease, a rare progressive neurological disorder. It remains one of September’s most closely watched rare-disease regulatory catalysts.

$GRALGalleriSep 23FDA panelAdCom on the multi-cancer MCED test PMA

GRAIL. FDA’s Molecular and Clinical Genetics Panel will meet on September 23 to discuss and vote on the Galleri premarket approval application. Galleri is a blood-based multi-cancer early detection test proposed for screening adults aged 50 and older. This is not a drug PDUFA; it is a device and diagnostics regulatory catalyst that is nevertheless material to the stock.

$MIRMzilurgisertibSep 26NDAFOP · patients aged 12 and older

Mirum Pharmaceuticals / Incyte. Priority Review PDUFA for the zilurgisertib NDA in fibrodysplasia ossificans progressiva in patients aged 12 years and older. Mirum holds exclusive worldwide rights under license from Incyte.

$BFRIAmeluz PDTSep 28sNDAExpansion into superficial BCC

Biofrontera. PDUFA for the Ameluz photodynamic-therapy sNDA in superficial basal cell carcinoma. FDA completed its filing review without identifying filing deficiencies and assigned September 28 as the target action date.

$SRRKapitegromabSep 30BLASMA · review continues with second fill-finish site

Scholar Rock. The apitegromab BLA in spinal muscular atrophy remains targeted to September 30. On August 7, the company said that, in coordination with FDA, Catalent Indiana is being removed from the BLA and review is continuing using the second fill-finish facility; the related data package is under review. CMC and manufacturing risk therefore remain central, while the company continues to state that the action date is unchanged.

$ROIVbrepocitinibQ3NDADermatomyositis · Priority Review

Priovant / Roivant. The brepocitinib NDA in dermatomyositis is under Priority Review. The company has disclosed a PDUFA target action date in the third quarter of 2026 and, if approved, has pointed to a possible U.S. launch around the end of September. No exact PDUFA day has been made public.

$QUREAMT-130Q3BLAAccelerated-approval BLA filing in Huntington’s disease

uniQure. The company is preparing an AMT-130 BLA in Huntington’s disease after alignment with FDA on a pathway that may use comparison with an external control as the primary basis of the application. The submission remains a Q3 2026 catalyst; it is not a PDUFA, and FDA filing acceptance would be the next formal step.

$SLNdivesiranAugDataSANRECO Phase 2 in polycythemia vera

Silence Therapeutics. Phase 2 SANRECO topline data for divesiran in polycythemia vera are expected in August. The readout also provides a particularly relevant class comparison with rusfertide from $PTGX / Takeda.

$TENXTNX-103AugPhase 3Registrational LEVEL study · PH-HFpEF

Tenax Therapeutics. Topline results from the registrational Phase 3 LEVEL study of TNX-103, oral levosimendan, in pulmonary hypertension associated with heart failure with preserved ejection fraction are expected in August 2026. The results are also scheduled for a Late-Breaking Clinical Science presentation at ESC on August 29.

$EYPTDURAVYU / LUGANOAugPhase 3Pivotal wet AMD topline

EyePoint. Phase 3 LUGANO topline data for DURAVYU (vorolanib intravitreal insert) in wet age-related macular degeneration are expected in August 2026. LUGANO is the first of two fully enrolled global pivotal trials comparing six-month DURAVYU dosing with on-label aflibercept; LUCIA is expected to read out in the fourth quarter. Key variables include visual-acuity noninferiority, supplemental anti-VEGF use, anatomy and ocular safety.

$IMMXNXC-201Late SepDataNEXICART-2 · AL amyloidosis

Immix Biopharma. The next NEXICART-2 update for NXC-201 in relapsed or refractory AL amyloidosis is expected in late September 2026. The program is designed as BLA-enabling/registrational, and subsequent follow-up is expected to contribute to the regulatory path.

$KPTIselinexor comboAugsNDASelinexor + ruxolitinib filing in myelofibrosis

Karyopharm. The former XPORT-EC-042 endometrial-cancer catalyst is resolved: on July 30, the study did not meet its primary progression-free-survival endpoint. The active event is now the sNDA the company plans to submit in August for selinexor combined with ruxolitinib in myelofibrosis, with a request for Priority Review.

$KODDAYBREAKSepPhase 3Wet AMD · Zenkuda and KSI-501

Kodiak Sciences. One-year primary-endpoint topline results from the Phase 3 DAYBREAK study in wet age-related macular degeneration are expected in September 2026. The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 in parallel against aflibercept.

$ALMSenvudeucitinibQ3DataLUMUS Phase 2b in SLE

Alumis. Phase 2b LUMUS results for envudeucitinib in systemic lupus erythematosus are expected in the third quarter. For an autoimmune readout, the market will assess not only statistical significance but also dose consistency, clinical endpoints and the safety profile.

$IVVDVYD2311Q3DataDECLARATION pivotal study

Invivyd. Topline data from the pivotal Phase 3 DECLARATION study of VYD2311 are expected in the third quarter of 2026. The timing remains company guidance rather than a calendar-specific date.

$AMLXavexitideLate Aug / early SepPhase 3Pivotal LUCIDITY study in PBH

Amylyx. Topline results from the pivotal Phase 3 LUCIDITY study of avexitide in post-bariatric hypoglycemia are now expected in late August or early September 2026. The last participant has completed the final visit in the double-blind treatment period.

$PHVSdeucrictibant XRQ3Phase 3CHAPTER-3 · HAE prophylaxis

Pharvaris. Phase 3 CHAPTER-3 topline data for extended-release deucrictibant in hereditary-angioedema prophylaxis remain expected in the third quarter of 2026. This is one of the quarter’s most important registrational HAE readouts.

$SYRESPY003SepDataSKYLINE Phase 2 in ulcerative colitis

Spyre Therapeutics. SPY003 Part A topline data from the Phase 2 SKYLINE study in ulcerative colitis are expected in September 2026, according to the company’s August 4 update.

$VERATRUTAKNA / ataciceptQ3eGFRORIGIN 3 confirmatory follow-up

Vera Therapeutics. The ORIGIN 3 eGFR analysis is expected in the third quarter following accelerated approval of atacicept. This is not another approval decision; its significance lies in the durability of the renal effect and the read-through for the confirmatory pathway.

$XENEazetukalnerQ3NDAFocal-onset seizure filing

Xenon. The azetukalner NDA submission in focal-onset seizures remains on track for the third quarter. Filing confirmation would begin FDA’s filing-review stage and set up a later PDUFA assignment.

$BBIOinfigratinibQ3NDAAchondroplasia filing

BridgeBio. The company intends to submit the infigratinib NDA in achondroplasia in the third quarter. The immediate catalyst is the submission; FDA acceptance and any PDUFA date would follow.

$CLNNCNM-Au8Q3NDAAccelerated pathway in ALS

Clene. The company continues to target a third-quarter NDA submission for CNM-Au8 in amyotrophic lateral sclerosis through an accelerated-approval pathway. Regulatory risk remains high: a planned submission is not the same as FDA filing acceptance or approval.

$MLTXsonelokimabLate SepBLAHidradenitis suppurativa filing

MoonLake. The sonelokimab BLA submission in hidradenitis suppurativa is expected around the end of September 2026. FDA filing acceptance would create the next formal regulatory event.

Most attention-worthy watchlist

$NRXP$CAPR$RARE$PTGX$IONS$GRAL$MIRM$SRRK$TENX$EYPT$AMLX$PHVS$QURE$IMMX

Board rule

Only future or still materially unresolved catalysts through September are shown. $NRXP remains because first-cycle review of the KETAFREE ANDA ended with a residual container-closure certification request and no new exact action date. $SVRA has been removed because FDA extended the MOLBREEVI PDUFA date to November 22, 2026, outside this board. Resolved events for $REPL, $MRNA, $BIIB and $GSK/zidesamtinib have been removed, as have $MPLT’s completed ZEPHYR readout and the former Q3 $OCGN items now guided to 2027. For $KPTI, the completed endometrial-cancer readout has been replaced by the planned August myelofibrosis sNDA. The September 23 $GRAL/Galleri panel and the August $TENX LEVEL and $EYPT LUGANO readouts are included. Month-only and quarter-only windows reflect disclosed company guidance and are not exact FDA dates.

Educational content only — not investment advice or a recommendation to buy or sell securities. Verify dates and primary filings before trading around binary events.Full catalyst calendarFDASEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.